TWO · 4162.TWO
PharmaEngine, Inc.
NT$58.20+NT$1.50 (+2.65%)
PharmaEngine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
Loading market information…
TWO · 6785.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Alar Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Alar Pharmaceuticals Inc.’s forward annual dividend is NT$0.10 per share, paid annual. The forward yield is 0.12% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Alar Pharmaceuticals Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -NT$0.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alar Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$0.00-100.0% vs estimate |
| Q3 2024 | Nov 7, 2024 | -NT$0.22-15.79% vs estimate | NT$5.82M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$58.20+NT$1.50 (+2.65%)
PharmaEngine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
NT$45.40-NT$3.10 (-6.39%)
OBI Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.04% below the high.
NT$54.00-NT$1.70 (-3.05%)
Sinew Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.47% below the high.
NT$24.60-NT$0.20 (-0.81%)
Formosa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.13% below the high.
NT$27.10-NT$0.10 (-0.37%)
Pharmosa Biopharm Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.83% below the high.
NT$5.85-NT$0.09 (-1.52%)
Mercury Biopharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.05% below the high.
NT$32.25-NT$0.90 (-2.71%)
Andros Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 29.82% below the high.
NT$14.60-NT$0.35 (-2.34%)
Original BioMedicals Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 27.0% below the high.
